Annals of neurology
-
Annals of neurology · Mar 2019
Randomized Controlled TrialA randomized study of solriamfetol for excessive sleepiness in narcolepsy.
Solriamfetol (JZP-110) is a selective dopamine and norepinephrine reuptake inhibitor with wake-promoting effects. This phase 3 study (NCT02348593) evaluated the safety and efficacy of solriamfetol in narcolepsy. ⋯ Solriamfetol has the potential to be an important therapeutic option for the treatment of impaired wakefulness and excessive sleepiness in patients with narcolepsy. ANN NEUROL 2019;85:359-370.